Parkinson DiseasePhase 2NCT07370532
Etoricoxib in Patients With Parkinsonian Disease
A Phase 2 study testing L-dopa and Etoricoxib in people with Parkinson Disease, run by Ihab Elsayed Hassan at 1 site in Egypt.
Trial summary
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- L-dopa and Etoricoxib
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Jan 2026to 20 Nov 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years.
- Both male and female will be included.
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Who cannot join
- Breast feeding
- Patients with significant liver and kidney function abnormalities.
- Alcohol and / or drug abusers.
- Patients with known allergy to the study medications
- Pregnant women and women with planned pregnancy.
- Patients who are currently using other anti-inflammatory drugs.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Mansoura University
Al Mansurah, 26548
Ehab Hassan, PhD, 01067831661, Ehassan@horus.edu.eg
About this study
Official title: Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
- Conditions
- Parkinson Disease
- Being tested
- L-dopa, Etoricoxib
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
L-dopaDrug
Levodopa is the standard therapy in PD.
EtoricoxibDrug
Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Active comparator | (levo-dopa group, n =30) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months. Receives: Drug: L-dopa |
| Etoricoxib group | Active comparator | will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus Etoricoxib 90 mg once daily Receives: Drug: L-dopa; Drug: Etoricoxib |
What is being measured
The primary outcome is the main question the study is designed to answer.
- Change in The Unified Parkinson's Disease Rating Scale
- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2026
- Study start30 Jan 2026
- Primary completion10 Nov 2027 (estimated)
- Study completion20 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ihab Elsayed Hassan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ihab Elsayed Hassan, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07370532
- Sponsor's protocol ID
- 98658
- Status last verified
- Apr 2026
- First submitted
- 17 Jan 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
- ClinicalTrials.gov ID
- NCT07370532
- Acronym / sponsor ID
- 98658
- Conditions
- Parkinson Disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Ihab Elsayed HassanUniversity, hospital or other
- Study start
- 30 Jan 2026 (actual)
- Primary completion
- 10 Nov 2027 (estimated)
- Study completion
- 20 Nov 2027 (estimated)
- First posted
- 27 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group | Active comparator | Drug: L-dopa(levo-dopa group, n =30) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months. |
| Etoricoxib group | Active comparator | Drug: L-dopa, Drug: Etoricoxibwill receive levo-dopa/carbidopa (125/12.5) mg three times daily plus Etoricoxib 90 mg once daily |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥ 18 years.
- Both male and female will be included.
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Key exclusion criteria (6 listed)
- Breast feeding
- Patients with significant liver and kidney function abnormalities.
- Alcohol and / or drug abusers.
- Patients with known allergy to the study medications
- Pregnant women and women with planned pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| L-dopaLevodopa is the standard therapy in PD. | Drug | Control group, Etoricoxib group |
| EtoricoxibEtoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia. | Drug | Etoricoxib group |
Primary outcome
- Change in The Unified Parkinson's Disease Rating Scale
Time frame: 6 months
- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing L-dopa and Etoricoxib in people with Parkinson Disease, run by Ihab Elsayed Hassan at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
- Change in The Unified Parkinson's Disease Rating Scale (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.